Feature | June 02, 2014

St. Jude Medical Completes Acquisition of CardioMEMS

June 2, 2014 — St. Jude Medical announced the completion of its acquisition of the privately held CardioMEMS Inc., developer of the CardioMEMS heart failure (HF) management system. The acquisition was completed on May 30, 2014.

“St. Jude Medical’s acquisition of CardioMEMS shows our commitment to providing innovative medical device solutions that reduce the burden of complex diseases like heart failure, both on patients and healthcare systems. The CardioMEMS HF system achieves this goal by setting a new treatment paradigm for heart failure that reduces hospitalizations and improves the quality of life for patients,” said Daniel J. Starks, chairman, president and CEO of St. Jude Medical.

The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions when used by physicians to manage heart failure. St. Jude Medical will now begin its strategic launch of the CardioMEMS HF system in the United States.

The CardioMEMS HF system allows clinicians to stabilize pulmonary artery pressures by proactively managing medications and other treatment options while also providing an early indication of worsening heart failure, thereby improving heart failure patients’ quality of life, and reducing economic risks for hospitals and payers.

Bank of America Merrill Lynch acted as financial advisor and Gibson, Dunn & Crutcher LLP as legal counsel to St. Jude Medical. J.P. Morgan Securities LLC acted as financial advisor to CardioMEMS and Cooley LLP as legal counsel.

For more information: www.sjm.com

Related Content

Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM)| April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT)| April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Sponsored Content | Videos | EP Lab| April 10, 2017
A discussion with Heart Rhythm Society (HRS) President Michael Gold, M.D., Ph.D., director of cardiology and associat
SCAI, MEDCAC panel, health outcomes, heart failure, treatment technologies
News | Heart Failure| April 04, 2017
This week the Centers for Medicare & Medicaid Services (CMS) convened a panel of the Medicare Evidence Development...
Sponsored Content | Videos | ACC| April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
CardioMEMS, heart failure, PA pressure monitoring, ACC17
News | March 30, 2017
March 30, 2017 — New late-breaking featured clinical research presented today adds strong clinical support for Abbott
Acarix, CADScor System, coronary artery disease detection, clinical study, ACC.17
News | Patient Monitors| March 30, 2017
Acarix AB recently announced the results from a new multi-center trial of its handheld CADScor System for non-invasive...
Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection
Technology | Implantable Cardiac Monitor (ICM)| March 15, 2017
Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac...
marijuana use, increased risk, stroke, heart failure, ACC 2017 study
News | Stroke| March 15, 2017
Using marijuana raises the risk of stroke and heart failure even after accounting for demographic factors, other health...
Overlay Init